Kwality Pharmaceuticals Reports 32% Revenue Growth in H1 FY26, Expects Continued Momentum in Q3 FY26

Kwality Pharmaceuticals Ltd (KPL) reported a 32% year-on-year increase in consolidated revenue for the first half of FY26, reaching 224 crore from 170 crore in H1 FY25. The growth was driven by strong sales of registered products across key international markets. EBITDA increased by 35% year-on-year, from 37 crore in H1 FY25 to 250 crore in H1 FY26. Net profit rose from 17 cr in H1FY25 to 26 cr in H1FY26. The company accelerated its R&D and clinical initiatives, advanced its strategic capex program, and received multiple new product registrations during the quarter. KPL expects continued growth momentum in Q3 FY26, driven by higher order inflows, new product launches, and scale-up across international markets.